Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Cervical Cancer | Research

Cervical cancer screening utilization and its predictors among women in bench Sheko Zone, Southwest Ethiopia: using health belief model

Authors: Alemayehu Sayih Belay, Wondwossen Niguse Asmare, Aychew Kassie

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Cervical cancer is the fourth most frequently diagnosed and found to be the leading cause of cancer death in women, especially in low and middle-income countries. Even though cervical cancer is a preventable disease, its preventive measures have not been equitably implemented across and within different countries; especially in low and middle-income countries, due to different contributing factors.

Objective

This study aimed to assess cervical cancer screening utilization and its’ predictors among Women in Bench Sheko Zone, Southwest Ethiopia.

Method

A community-based cross-sectional study design was employed in Bench Sheko Zone from February 2021 to April 2021. Using a multi-stage stratified sampling method, a total of 690 women in the age range of 30–49 years were included in the study. The logistic regression analysis was used considering a 95% confidence interval and a P-value of < 0.05.

Results

Ninety-six (14.2%) of the participants have utilized cervical cancer screening. Predictors like; age between 40–49 years (AOR = 5.35, 95% CI = [2.89, 9.90]), partner educational status of certificate and above (AOR = 4.36, 95% CI = [1.65, 11.51]), first sexual intercourse before eighteen years (AOR = 4.85, 95% CI = [2.29, 10.26]), ever used of alcohol (AOR = 3.99, 95% CI = [1.23, 12.89]), good knowledge (AOR = 8.98, 95% CI = [4.06, 19.89]), favorable attitude (AOR = 3.56, 95% CI = [1.78, 7.09]), and high perceived benefit (AOR = 2.94, 95% CI = [1.48, 5.84]) were strongly associated with cervical cancer screening utilization.

Conclusion

In this study, cervical cancer screening utilization was relatively low. Therefore, promotion of the perception of women towards cervical cancer screening, and provision of health-related information towards different behavioral-related factors should have to be addressed at each level of health care.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2.
WHO. Africa - Global Cancer Observatory (GLOBOCAN 2020). 2020.
3.
4.
5.
Castle PE, Einstein MH, Sahasrabuddhe VV. Cervical cancer prevention and control in women living with human immunodeficiency virus. CA: a cancer journal for clinicians. 2021;71(6):505–26.
6.
Chattopadhyay K, Williamson A-L, Hazra A, Dandara C. The combined risks of reduced or increased function variants in cell death pathway genes differentially influence cervical cancer risk and herpes simplex virus type 2 infection among black Africans and the Mixed Ancestry population of South Africa. BMC Cancer. 2015;15:1–7.CrossRef
7.
Zhu H, Shen Z, Luo H, Zhang W, Zhu X. Chlamydia trachomatis infection-associated risk of cervical cancer: a meta-analysis. Medicine. 2016;95(13).
8.
Klein C, Kahesa C, Mwaiselage J, West JT, Wood C, Angeletti PC. How the cervical microbiota contributes to cervical cancer risk in sub-Saharan Africa. Front Cell Infect Microbiol. 2020;10:23.PubMedPubMedCentralCrossRef
9.
Muntyanu A, Nechaev V, Pastukhova E, Logan J, Rahme E, Netchiporouk E, et al. Risk factors and communities disproportionately affected by cervical cancer in the Russian Federation: A national population-based study. The Lancet Regional Health-Europe. 2022;20: 100454.PubMedPubMedCentralCrossRef
10.
11.
Liu Z-C, Liu W-D, Liu Y-H, Ye X-H, Chen S-D. Multiple sexual partners as a potential independent risk factor for cervical cancer: a meta-analysis of epidemiological studies. Asian Pac J Cancer Prev. 2015;16(9):3893–900.PubMedCrossRef
12.
13.
Rahmawati DL, Rahayu DE, Hardjito K. Correlation between Oral Contraceptive Use and the Incidence of Cervical Cancer. Poltekita: Jurnal Ilmu Kesehatan. 2023;16(4):497–504.
14.
Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus. 2017;26(7):682–9.PubMedCrossRef
15.
Lemp JM, De Neve J-W, Bussmann H, Chen S, Manne-Goehler J, Theilmann M, et al. Lifetime Prevalence of Cervical Cancer Screening in 55 Low-and Middle-Income Countries. JAMA. 2020;324(15):1532–42.PubMedPubMedCentralCrossRef
16.
Gelibo T, Roets L, Getachew T, Bekele A. Coverage and factors associated with cervical cancer screening: results from a population-based WHO steps study in Ethiopia. Adv Oncol Res Treat. 2017;1(115):2.
17.
NCDs WT. best buys’ and other recommended interventions for the prevention and control of noncommunicable diseases. Geneva: World Health Organization. 2017.
18.
Organization WH. WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. 2019.
19.
20.
Shiferaw N, Salvador-Davila G, Kassahun K, Brooks MI, Weldegebreal T, Tilahun Y, et al. The single-visit approach as a cervical cancer prevention strategy among women with HIV in Ethiopia: successes and lessons learned. Global Health: Science and Practice. 2016;4(1):87–98.PubMed
21.
Kasim J, Kalu A, Kamara B, Alema HB. Cervical Cancer screening service utilization and associated factors among women in the Shabadino District, Southern Ethiopia. Journal of Cancer Epidemiology. 2020;2020.
22.
Nigussie T, Admassu B, Nigussie A. Cervical cancer screening service utilization and associated factors among age-eligible women in Jimma town using health belief model. South West Ethiopia BMC women’s health. 2019;19(1):1–10.
23.
Muluneh BA, Atnafu DD, Wassie B. Predictors of cervical cancer screening service utilization among commercial sex workers in Northwest Ethiopia: a case-control study. BMC Womens Health. 2019;19(1):1–9.CrossRef
24.
Teame H, Gebremariam L, Kahsay T, Berhe K, Gebreheat G, Gebremariam G. Factors affecting utilization of cervical cancer screening services among women attending public hospitals in Tigray region, Ethiopia, 2018; case control study. PLoS ONE. 2019;14(3): e0213546.PubMedPubMedCentralCrossRef
25.
Aynalem BY, Anteneh KT, Enyew MM. Utilization of cervical cancer screening and associated factors among women in Debremarkos town, Amhara region, Northwest Ethiopia: Community based cross-sectional study. PLoS ONE. 2020;15(4): e0231307.PubMedPubMedCentralCrossRef
26.
Belay Y, Dheresa M, Sema A, Desalew A, Assefa N. Cervical Cancer Screening Utilization and Associated Factors Among Women Aged 30 to 49 Years in Dire Dawa, Eastern Ethiopia. Cancer Control. 2020;27(1):1073274820958701.PubMedPubMedCentralCrossRef
27.
Idowu A, Olowookere SA, Fagbemi AT, Ogunlaja OA. Determinants of cervical cancer screening uptake among women in Ilorin, North Central Nigeria: a community-based study. Journal of cancer epidemiology. 2016;2016.
28.
Mugassa AM, Frumence G. Factors influencing the uptake of cervical cancer screening services in Tanzania: A health system perspective from national and district levels. Nurs Open. 2020;7(1):345–54.PubMedCrossRef
29.
Tigeneh W, Molla A, Abreha A, Assefa M. Pattern of cancer in Tikur Anbessa specialized hospital oncology center in Ethiopia from 1998 to 2010. Int J Cancer Res Mol Mech. 2015;1(1):1.
30.
Binka C, Nyarko SH, Awusabo-Asare K, Doku DT. Barriers to the uptake of cervical cancer screening and treatment among rural women in Ghana. Biomed Res Int. 2019;2019:1–8.CrossRef
31.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424.
32.
Ncube B, Bey A, Knight J, Bessler P, Jolly PE. Factors associated with the uptake of cervical cancer screening among women in Portland, Jamaica. N Am J Med Sci. 2015;7(3):104.PubMedPubMedCentralCrossRef
33.
Fontham ET, Wolf AM, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians. 2020;70(5):321–46.
34.
Mendes D, Mesher D, Pista A, Baguelin M, Jit M. Understanding differences in cervical cancer incidence in Western Europe: comparing Portugal and England. The European Journal of Public Health. 2018;28(2):343–7.PubMedCrossRef
35.
Glanz K, Rimer BK, Viswanath K. Health behavior and health education: theory, research, and practice: Wiley; 2008.
36.
Rosenstock IM. Historical origins of the health belief model. Health Educ Monogr. 1974;2(4):328–35.CrossRef
37.
Federal Democratic Republic of Ethiopia Ministry of Health. Guideline for Cervical Cancer Prevention and Control in Ethiopia. 2015.
38.
Gebreegziabher M, Asefa NG, Berhe S, Factors affecting the practices of cervical cancer screening among female nurses at public health institutions in Mekelle town, Northern Ethiopia,. a cross-sectional study. J Cancer Res. 2014;2016:2016.
39.
Kileo NM, Michael D, Neke NM, Moshiro C. Utilization of cervical cancer screening services and its associated factors among primary school teachers in Ilala Municipality, Dar es Salaam. Tanzania BMC Health Serv Res. 2015;15(1):1–9.
40.
Segni MT, Demissie HF, Tadesse DM, Amdemichael R, Mamo YT, Worku A. Level of knowledge and associated factor toward cervical cancer among women age (21–64) years visiting health facilities in Gulele sub-city Addis Ababa Ethiopia. J Pancreas. 2017;18(1):44–8.
41.
Ibekwe CM, Hoque ME, Ntuli-Ngcobo B. Perceived susceptibility of cervical cancer screening among women attending Mahalapye district hospital. Botswana Southern African J Epidemiol Infect. 2010;25(2):16–21.CrossRef
42.
43.
Hoque M, Ibekwe C, Ntuli-Ngcobo B. Screening and perceived severity of cervical cancer among women attending Mahalapye District Hospital. Botswana Asian Pacific J Cancer Prev. 2009;10(6):1095–100.
44.
Ibekwe C, Hoque M, Ntuli-Ngcobo B. Perceived benefits of cervical cancer screening among women attending Mahalapye District Hospital. Botswana Asian Pac J Cancer Prev. 2010;11(4):1021–7.PubMed
45.
Ibekwe C, Hoque M, Ntuli-Ngcobo B, Hoque M. Perceived barriers of cervical cancer screening among women attending Mahalapye district hospital, Botswana. Arch Clin Microbiol. 2011;2(1):4.
46.
Kibicho JW. Factors influencing utilization of cervical cancer screening services in Embu hospital, Embu county. Kenya: University of Nairobi; 2014.
47.
Bekela E. Assessment of knowledge and attitude of cervical cancer and screening among primary health care workers of West Wollega Zone, Ethiopia, 2016: Addis Ababa University; 2016.
48.
49.
Organization WH. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention: World Health Organization; 2013.
50.
Wanyenze RK, Bwanika JB, Beyeza-Kashesya J, Mugerwa S, Arinaitwe J, Matovu JK, et al. Uptake and correlates of cervical cancer screening among HIV-infected women attending HIV care in Uganda. Glob Health Action. 2017;10(1):1380361.PubMedPubMedCentralCrossRef
51.
Ifemelumma C, Anikwe C, Okorochukwu B, Onu F, Obuna J, Ejikeme B, et al. Cervical cancer screening: assessment of perception and utilization of services among health workers in low resource setting. International J Reprod Med. 2019;2019.
52.
Lyimo FS, Beran TN. Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: three public policy implications. BMC Public Health. 2012;12(1):1–8.CrossRef
53.
Tekle T, Wolka E, Nega B, Kumma WP, Koyira MM. Knowledge, attitude and practice towards cervical cancer screening among women and associated factors in Hospitals of Wolaita Zone. Southern Ethiopia Cancer Manag Res. 2020;12:993.PubMedCrossRef
54.
Getachew S, Getachew E, Gizaw M, Ayele W, Addissie A, Kantelhardt EJ. Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. PLoS ONE. 2019;14(5): e0216522.PubMedPubMedCentralCrossRef
55.
Erku DA, Netere AK, Mersha AG, Abebe SA, Mekuria AB, Belachew SA. Comprehensive knowledge and uptake of cervical cancer screening is low among women living with HIV/AIDS in Northwest Ethiopia. Gynecologic Oncol Res Practice. 2017;4(1):1–7.
56.
Ebu NI, Mupepi SC, Siakwa MP, Sampselle CM. Knowledge, practice, and barriers toward cervical cancer screening in Elmina. Southern Ghana Int J Womens Health. 2015;7:31.PubMed
57.
Gebru Z, Gerbaba M, Dirar A. Utilization of cervical carcinoma screening service and associated factors among currently married women in Arba Minch Town, Gamo Gofa Zone, Southern Ethiopia 2014.
58.
Chosamata MS, Hong S, Tiraphat S. Determinants of cervical cancer screening utilization among women aged 30–45 years in Blantyre district. Malawi J Public Health Dev. 2015;13(3):19–34.
59.
Bayu H, Berhe Y, Mulat A, Alemu A. Cervical cancer screening service uptake and associated factors among age eligible women in Mekelle Zone, Northern Ethiopia, 2015: a community based study using health belief model. PLoS ONE. 2016;11(3): e0149908.PubMedPubMedCentralCrossRef
60.
Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet. 2002;359(9312):1093–101.PubMedCrossRef
61.
Kokuro M. Factors affecting the utilisation of cervical cancer screening among women attending health services in the kumasi metropolis of ghana: Stellenbosch: Stellenbosch University; 2017.
62.
Morema EN, Atieli HE, Onyango RO, Omondi JH, Ouma C. Determinants of cervical screening services uptake among 18–49 year old women seeking services at the Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu. Kenya BMC Health Serv Res. 2014;14(1):1–7.
63.
Mu L, Mukamal KJ. Alcohol consumption and rates of cancer screening: Is cancer risk overestimated? Cancer Causes Control. 2016;27(2):281–9.PubMedCrossRef
64.
Weiderpass E, Ye W, Tamimi R, Trichopolous D, Nyren O, Vainio H, et al. Alcoholism and risk for cancer of the cervix uteri, vagina, and vulva. Cancer Epidemiol Prev Biomarkers. 2001;10(8):899–901.
65.
Mbaka P, Waihenya R, Oisebe C, Lihana R. Factors affecting the uptake of cervical cancer screening in Mama Lucy Kibaki Hospital, Nairobi. Kenya Cancer Res J. 2018;6:106.CrossRef
66.
Oba S, Toyoshima M, Ogata H. Association of cervical cancer screening with knowledge of risk factors, access to health related information, health profiles, and health competence beliefs among community-dwelling women in Japan. Asian Pacific J Cancer Prev: APJCP. 2017;18(8):2115.
67.
Leung SS, Leung I. Cervical cancer screening: knowledge, health perception and attendance rate among Hong Kong Chinese women. Int J Womens Health. 2010;2:221.PubMedPubMedCentralCrossRef
68.
Geremew AB, Gelagay AA, Azale T. Uptake of pre cervical cancer screening service and associated factors among women aged 30–49 years in Finote Selam town Northwest Ethiopia. Int J Collab Res Intern Med Public Health. 2018;10(2):0-.
69.
Assefa AA, Astawesegn FH, Eshetu B. Cervical cancer screening service utilization and associated factors among HIV positive women attending adult ART clinic in public health facilities, Hawassa town, Ethiopia: a cross-sectional study. BMC Health Serv Res. 2019;19(1):1–11.CrossRef
70.
Maddux JE, Rogers RW. Protection motivation and self-efficacy: A revised theory of fear appeals and attitude change. Journal of Exp Soc Psych. 1983;19(5):469–79.CrossRef
71.
Feyisa GC, Temesgen H. Perceived benefits and barriers toward cervical cancer screening among women≥ 15 years in Arsi Zone, Southeastern Ethiopia: Application of the health belief model in a community-based cross-sectional study. J Cancer Res Pract. 2019;6(1):7.CrossRef
Metadata
Title
Cervical cancer screening utilization and its predictors among women in bench Sheko Zone, Southwest Ethiopia: using health belief model
Authors
Alemayehu Sayih Belay
Wondwossen Niguse Asmare
Aychew Kassie
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10927-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients

Research

FAP, CD10, and GPR77-labeled CAFs cause neoadjuvant chemotherapy resistance by inducing EMT and CSC in gastric cancer

Research

CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells

Research

Overall survival of patients with hepatocellular carcinoma treated with sintilimab and disease outcome after treatment discontinuation

Research

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer

Research

Optimized screening of DNA methylation sites combined with gene expression analysis to identify diagnostic markers of colorectal cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits